Russian researchers have announced the development of a breakthrough cancer vaccine that is now prepared for clinical use. The Federal Medical and Biological Agency (FMBA) confirmed the progress at the 10th Eastern Economic Forum, where agency head Veronika Skvortsova shared the results of years of scientific work.
The vaccine, named Enteromix, relies on mRNA technology — the same platform used to produce some of the most widely deployed COVID-19 vaccines. Unlike traditional vaccines that employ weakened viruses, mRNA-based treatments train the body’s own cells to generate proteins capable of stimulating a targeted immune response against malignant tumors.
According to Skvortsova, the project has undergone extensive research, including three years of mandatory preclinical studies. Results indicated not only high safety levels, even with repeated administration, but also significant effectiveness. Depending on the cancer type, tumor reduction or slowed growth ranged from 60% to 80%. Researchers also reported a marked improvement in survival rates among experimental models.
The initial application of Enteromix will target colorectal cancer, one of the most common malignancies worldwide. Parallel research is also advancing toward vaccines for aggressive conditions such as glioblastoma, as well as melanoma, including ocular melanoma, a rare form affecting the eye.
The announcement was made at a forum that attracted over 8,400 participants from more than 75 countries, underscoring global interest in cutting-edge medical innovations.
